Recent developments in acute myelogenous leukemia therapy

被引:20
作者
King, Mary E.
Rowe, Jacob M.
机构
[1] Med & Sci Commun, Boulder, CO USA
[2] Technion Israel Inst Technol, Rambam Med Ctr, Dept Hematol & BMT, Haifa, Israel
关键词
acute myelogenous leukemia; cytogenetic abnormalities; bone marrow transplantation; hematopoietic stem cell transplantation; transplantation conditioning; biological therapy;
D O I
10.1634/theoncologist.12-S2-14
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent progress has been made in several areas in the treatment of acute myelogenous leukemia (AML): prognostic factors, allogeneic bone marrow transplantation, and new and targeted therapies. Delineation and clarification of prognostic factors have led to improved risk determination, with research moving from cytogenetics to an examination of molecular markers. Trends in the area of allogeneic bone marrow transplantation include broad adoption of reduced-intensity conditioning despite the lack of prospective comparative studies. Although the preponderance of data has established this as a feasible option, a true understanding of how much of an advantage it conveys needs to be established in prospective studies. The use of alternative donors is another advance, and recent data are promising, but survival is poor if transplantation is performed when disease is active, especially during refractory relapse or refractory disease. When haploidentical matched donors are used, survival rates appear similar to those reported with matched unrelated-donor transplants. Analysis of the data for allogeneic transplantation shows that HLA-identical sibling transplants to patients in the first complete remission (CRI) provide the highest probability of long-term survival, compared with HLA-identical sibling transplants to patients in later remissions. Similarly, unrelated-donor transplants to high-risk patients in CRI lead to a greater degree of success than unrelated-donor transplants to patients in CR2 or later remission. Cord blood has also been established as a suitable source for hematopoietic transplantation in AML. A third area of recent progress involves new and targeted therapies. Multiple new agents with tremendous potential are in development and clinical trials. Therapy can even be tailored to several specific genetic subtypes of AML.
引用
收藏
页码:14 / 21
页数:8
相关论文
共 41 条
  • [21] Krauter J, 2006, BLOOD, V108, p132A
  • [22] A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
    Lancet, Jeffrey E.
    Gojo, Ivana
    Gotlib, Jason
    Feldman, Eric J.
    Greer, Jacqueline
    Liesveld, Jane L.
    Bruzek, Laura M.
    Morris, Lawrence
    Park, Youn
    Adjei, Alex A.
    Kaufmann, Scott H.
    Garrett-Mayer, Elizabeth
    Greenberg, Peter L.
    Wright, John J.
    Karp, Judith E.
    [J]. BLOOD, 2007, 109 (04) : 1387 - 1394
  • [23] Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors.
    Laughlin, MJ
    Barker, J
    Bambach, B
    Koc, ON
    Rizzieri, DA
    Wagner, JE
    Gerson, SL
    Lazarus, HM
    Cairo, M
    Stevens, CE
    Rubinstein, P
    Kurtzberg, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (24) : 1815 - 1822
  • [24] Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma
    Majhail, NS
    Weisdorf, DJ
    Wagner, JE
    Defor, TE
    Brunstein, CG
    Burns, LJ
    [J]. BLOOD, 2006, 107 (09) : 3804 - 3807
  • [25] Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia -: Part I.: In vivo studies
    Malek, K
    Boosalis, MS
    Waraska, K
    Mitchell, BS
    Wright, DG
    [J]. LEUKEMIA RESEARCH, 2004, 28 (11) : 1125 - 1136
  • [26] Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
    Marcucci, G
    Byrd, JC
    Dai, GW
    Klisovic, MI
    Kourlas, PJ
    Young, DC
    Cataland, SR
    Fisher, DB
    Lucas, D
    Chan, KK
    Porcu, P
    Lin, ZP
    Farag, SF
    Frankel, SR
    Zvviebel, JA
    Kraut, EH
    Balcerzak, SP
    Bloomfield, CD
    Grever, MR
    Caligiuri, MA
    [J]. BLOOD, 2003, 101 (02) : 425 - 432
  • [27] Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
    McSweeney, PA
    Niederwieser, D
    Shizuru, JA
    Sandmaier, BM
    Molina, AJ
    Maloney, DG
    Chauncey, TR
    Gooley, TA
    Hegenbart, U
    Nash, RA
    Radich, J
    Wagner, JL
    Minor, S
    Appelbaum, FR
    Bensinger, WI
    Bryant, E
    Flowers, MED
    Georges, GE
    Grumet, FC
    Kiem, HP
    Torok-Storb, B
    Yu, G
    Blume, KG
    Storb, RF
    [J]. BLOOD, 2001, 97 (11) : 3390 - 3400
  • [28] Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22)
    Nanri, T
    Matsuno, N
    Kawakita, T
    Suzushima, H
    Kawano, F
    Mitsuya, H
    Asou, N
    [J]. LEUKEMIA, 2005, 19 (08) : 1361 - 1366
  • [29] Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML
    Nishii, K
    Usui, E
    Katayama, N
    Lorenzo, VF
    Nakase, K
    Kobayashi, T
    Miwa, H
    Mizutani, M
    Tanaka, I
    Nasu, K
    Dohy, H
    Kyo, T
    Taniwaki, M
    Ueda, T
    Kita, K
    Shiku, H
    [J]. LEUKEMIA, 2003, 17 (04) : 731 - 737
  • [30] Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21):: A Cancer and Leukemia Group B study
    Paschka, Peter
    Marcucci, Guido
    Ruppert, Amy S.
    Mrozek, Krzysztof
    Chen, Hankui
    Kittles, Rick A.
    Vukosavljevic, Tamara
    Perrotti, Danilo
    Vardiman, James W.
    Carroll, Andrew J.
    Kolitz, Jonathan E.
    Larson, Richard A.
    Bloomfield, Clara D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) : 3904 - 3911